A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Ataluren (Primary)
- Indications Muscular dystrophies
- Focus Adverse reactions
- Sponsors PTC Therapeutics
- 20 Jul 2017 This study has been completed in Spain, according to the European Clinical Trials Database record.
- 30 May 2017 Status changed from recruiting to active, no longer recruiting.
- 15 May 2014 New trial record